Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06585462
PHASE1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Sponsor: Amgen

View on ClinicalTrials.gov

Summary

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2024-09-09

Completion Date

2026-10-01

Last Updated

2026-02-13

Healthy Volunteers

Yes

Interventions

DRUG

AMG 513

AMG 513 will be administered by SC or IV injection.

DRUG

Placebo

Placebo will be administered by SC or IV injection.

DRUG

AMG 513

AMG 513 will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection.

Locations (5)

Anaheim Clinical Trials

Anaheim, California, United States

Carilion Medical Center

Lake Forest, California, United States

Fomat Medical Research

Oxnard, California, United States

Translational Clinical Research LLC

Aventura, Florida, United States

Clinical Pharmacology of Miami, LLC

Miami, Florida, United States